Back to search results

A Study of INCB123667 for Platinum-Resistant Ovarian Cancer

This study is looking at a drug called INCB123667 for women with ovarian cancer that has become resistant to platinum-based chemotherapy. You may be able to join if you are between 18 and 99 years old, have a specific type of ovarian, fallopian tube, or primary peritoneal cancer, and your cancer is considered platinum-resistant. The study aims to see how well INCB123667 works by measuring if tumors shrink or disappear (Objective Response). The study plans to enroll 160 participants, but its current status is unclear.

Study design
This study is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 160 participants.
What's involved
Participants will take INCB123667 by mouth twice a day. The study will measure how well the treatment works for up to 2 years.
Compensation
Not stated in the trial record.
Follow-up
The study will measure how well the treatment works for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07023627

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Recruiting
PHASE2Ages 18–99InterventionalTreatment
Incyte Corporation
~160 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:INCB123667

At a glance

Recruiting sites
71 of 74 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response by IRC
Measured over Up to 2 years

Conditions

Ovarian Cancer

Explore related trials

Malignant Ovarian NeoplasmG1/S-Specific Cyclin-E1

Where it's being run

74 sites across 37 states
Spain10
Japan7
Belgium5
Florida4
Switzerland4
United Kingdom4
Ohio3
Texas3

Study leadership

  • Incyte Medical Monitor · STUDY_DIRECTOR · Incyte Corporation

Who to contact

Incyte Corporation Call Center (US)
[email protected]
1.855.463.3463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Have platinum-resistant disease:
Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen.
Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.
Willingness to undergo a pretreatment biopsy. Note: Tissue from a fresh pretreatment biopsy is preferred, however an archival sample is acceptable as long as the sample is no older than 5 years.
Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent therapy is considered an appropriate next therapeutic option.
Must have received bevacizumab unless there was a contraindication for its use.
If the tumor tests positive for FRα, participants must have received mirvetuximab soravtansine unless there is an exception for its use on medical grounds.

Exclusion

Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer.
Have primary platinum-refractory disease: either did not respond (CR or PR) to first-line platinum-containing therapy or progressed on or within 3 months after the last dose of the first line platinum-containing therapy.
The tumor tests positive for FRα but the participant has not received mirvetuximab soravtansine for any reason other than medical contraindication.
Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study drug.
Known active CNS metastases and/or carcinomatous meningitis.
Known additional malignancy that is progressing or requires active treatment.

What this trial measures

  • Objective Response by IRCUp to 2 years

    Defined as having a confirmed best overall response of complete response (CR) or partial response (PR), as determined by independent review committee (IRC) assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.